Navigation Links
Simultaneous Applications Submitted to FDA and EMA for Siltuximab for the Treatment of Multicentric Castleman Disease, a Rare Blood Disorder
Date:9/3/2013

RARITAN, N.J., Sept. 3, 2013 /PRNewswire/ -- Janssen Research & Development, LLC ("Janssen") announced the simultaneous submissions of a Biologic License Application (BLA) to the United States Food and Drug Administration (U.S. FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for siltuximab for the treatment of patients with multicentric Castleman disease (MCD) who are HIV-negative and human herpes virus-8 (HHV-8)-negative.

MCD is a rare disorder in which lymphocytes, a certain type of white blood cells, are over-produced and lead to enlargement of lymph nodes.1, 2 This can cause a variety of symptoms and weaken the immune system, making it hard to fight infection. Infections in people with MCD can be very serious and may even be fatal.3 Currently, there are no approved treatments in the U.S. or European Union (EU) for this rare blood disorder.

"We're proud of our work on siltuximab. As a rare disease with a small patient population, MCD is an area of significant unmet need," said Peter F. Lebowitz, M.D., Ph.D., global oncology therapeutic area head, Janssen. "Siltuximab works by targeting interleukin-6 which appears to be the critical driver of this disease. By focusing on core biologic mechanisms, we now have the potential of helping patients with a condition that is challenging to treat."  

Siltuximab has been granted orphan drug status in MCD in the U.S. and EU. The siltuximab regulatory submissions include data from a randomized, multi-national, double-blind, placebo-controlled study (MCD2001) and data from two non-randomized supportive studies. The MCD2001 study assessed the efficacy and safety of siltuximab plus best supportive care (BSC) compared with placebo plus BSC in patients with MCD.4 In the study, 79 patients were randomly assigned in a 2:1 ratio to one of the two treatment
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. First Large-Scale Population-Based Study in the U.S. Shows Hologics 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection
2. Philips IMR offers new capabilities to simultaneously reduce CT Radiation and enhance image quality
3. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
4. Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications
5. Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
6. Clinical Safety Data for ChromaDex®s Patented pTeroPure® (pterostilbene) Released at 6th World Congress on Polyphenols Applications in Paris
7. UltraTape announces Cleanroom Labels for Cryogenic Laboratory applications
8. New, Affordable Flow Cytometer Cell Sorter Expands Access to Wider Range of Life Science Applications
9. New Wireless Keyboard Rechargeable, Washable for Healthcare Applications
10. Frost & Sullivan: Label-Free Technology is a High Potential Market with Myriad Unexplored Applications
11. Radiotherapy Devices Market By Technology, Applications & Products (2011 - 2016)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015   NineSigma the leading ... over $450M in estimated overall revenue growth and anticipates the ... Third Frontier Open Innovation Incentive (OII). In ... NineSigma a grant of over $2 million to accelerate adoption ... between $10 Million and $1 Billion in revenues. To date ...
(Date:8/27/2015)... 2015 The nation,s newest Actos trial gets underway ... Vegas courtroom.  Attorneys representing two southern ... effects, including death, after using the diabetes drug Actos. ... a company knew, that their drug Actos caused an increased ... "In order to hold Takeda responsible it is appropriate to ...
(Date:8/27/2015)... CAESAREA, Israel , August 27, 2015 ... Equity today announced a private investment in public equity ... up to $28.4 million in Itamar Medical.   ... the largest shareholder of Itamar Medical and will work ... market expansion. According to the investment agreement, ...
Breaking Medicine Technology:State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 2State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 32 Billion Dollar Verdict Sought In Actos Trial 2Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 2Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 4Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 5
... Holdings, Inc. (NYSE: ZMH ; SIX: ZMH) today ... the 26th North American Spine Society Annual Meeting in Chicago, ... waist providing clinicians with clear and direct visualization during implant ... 2mm) which clinical literature suggests is one of the factors ...
... Inc. (Hologic or the Company) (NASDAQ: HOLX ... diagnostics products, medical imaging systems and surgical products dedicated ... that it has appointed Christiana Stamoulis to the Company,s ... on the Company,s Corporate Development Committee. Ms. ...
Cached Medicine Technology:Zimmer Introduces inViZia™ Anterior Cervical Plate System at NASS Annual Meeting 2Zimmer Introduces inViZia™ Anterior Cervical Plate System at NASS Annual Meeting 3Hologic Announces Appointment of New Director 2
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... confirmed today that its Krames Patient Education content is ICD-10 ready and available ... ready for the new ICD-10 code sets, which are more targeted and return ...
(Date:8/27/2015)... ... August 27, 2015 , ... Zensah®, the ... professional Tennis player for Israel in the Women’s Tennis Association (WTA). Glushko competes ... training and recovery. , With a focus on technology and comfort, Zensah® has ...
(Date:8/27/2015)... ... August 27, 2015 , ... In addition to its existing Doctor of Philosophy ... doctoral program at its main campus in Reading: Doctor of Nursing Practice. , Alvernia’s ... prepare advanced practice nurses for the highest level of clinical nursing practice. , ...
(Date:8/27/2015)... CT and OKLAHOMA CITY, OK (PRWEB) , ... ... ... Great Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract development ... to be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... ... August 27, 2015 , ... Market ... market research promotion on the Internet. MarketPublishers.com is now authorised to distribute ... the partnership agreement, Natalie Aster, Assistant Manager at Partners Department, noted: "Black ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... among those who drink 100% juice, but not all experts ... Children who drink 100 percent fruit juices apparently don,t tend ... than kids who don,t drink the beverages, a new study ... children," said lead researcher Theresa A. Nicklas, a professor of ...
... June 3 The nonpartisan Employee,Benefit Research Institute ... estimates of the amount of money individuals and ... in retirement. The new estimates,attempt to provide more ... with the financial consequences of longevity and investment ...
... 67% Say Less Likely to Re-Elect Member of ... WASHINGTON, June 3 As Congress prepares to,reconvene ... the,American Health Care Association (AHCA) released the results ... that seventy percent of,likely U.S. voters oppose an ...
... Market competition is,mounting to win the time, attention ... research shows that the most sought-after,clinical investigation sites ... they receive at their labs and clinics. Consequently,leading ... the art,and science of investigator recruitment., The ...
... of Women Business Owners Members Voice Their,Opinions on National ... state of the,economy, the cost and availability of health ... are the top issues impacting the,women,s business community at ... the National Association of Women Business Owners(R),(NAWBO(R)) among its ...
... area , , TUESDAY, June 3 (HealthDay News) -- When ... system to target malignancies, it was hoped that the therapy ... without affecting healthy tissue. , While the original theory is ... effects. , The findings, published in the June 10 issue ...
Cached Medicine News:Health News:Fruit Juice May Be Healthy for Kids: Study 2Health News:Fruit Juice May Be Healthy for Kids: Study 3Health News:New Research From EBRI: Estimates Show More Precise Retiree Health Savings Needs 2Health News:New Research From EBRI: Estimates Show More Precise Retiree Health Savings Needs 3Health News:New Research From EBRI: Estimates Show More Precise Retiree Health Savings Needs 4Health News:New Research From EBRI: Estimates Show More Precise Retiree Health Savings Needs 5Health News:70% of U.S. Voters Oppose Administration's Cuts to Medicare-Financed Nursing Home Care 2Health News:Best Practice Toolkit Supports Recruitment of Top Clinical Investigators 2Health News:Economy, Health Care, and Gas Prices Top Issues for Women Business Owners 2Health News:Dangerous Side Effect Found in Cancer Immunotherapy Research 2
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... The Blue Line UNO Splint fits small, medium, ... cushioned two-part design includes both dorsal and volar ... extension. Recommended for those experiencing symptoms of Carpal ... for busy clinics - stock one splint to ...
Comfort Wrist Immobilizer with thumb abduction. 8"L, soft, padded comfort-type wrist immobilizer with dorsal metal stay. The thumb is held in abduction and splintered with a short metal stay....
Medicine Products: